A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) Plus Thalidomide (Low Dose) as Frontline Therapy for Newly Diagnosed Patients With Multiple Myeloma (MM)

NCT00054158 Phase 2 COMPLETED

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining chemotherapy with thalidomide may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and thalidomide in treating patients who have newly diagnosed stage I, stage II, or stage III multiple myeloma.

Details

Lead sponsor	Roswell Park Cancer Institute
Phase	Phase 2
Status	COMPLETED
Enrolment	24
Start date	2004-08

Conditions

• Multiple Myeloma and Plasma Cell Neoplasm

Interventions

• dexamethasone
• doxorubicin hydrochloride
• thalidomide
• vincristine sulfate

Countries

United States